Head and neck cancer
Medical Radiology, ISSN: 2197-4187, Page: 91-126
2018
- 5Citations
- 156Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
In this chapter, various altered fractionation schedules are categorized and discussed within the landscape of clinical trials. Today, modern radiotherapy (RT) techniques are offering new avenues to exploit the advantages of altered fractionation not only for the primary treatment of treatment-naïve patients, but also in reirradiation and palliative situations. Novel agents, which are at least as effective but less toxic than platinum compounds, can be combined with contemporary RT techniques to widen the therapeutic window. Radiotherapy with altered fractionation, both alone or as part of combined modalities with systemic therapy (ST), offers many opportunities to the head and neck oncologists.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85054321566&origin=inward; http://dx.doi.org/10.1007/174_2017_32; http://link.springer.com/10.1007/174_2017_32; http://link.springer.com/content/pdf/10.1007/174_2017_32; https://dx.doi.org/10.1007/174_2017_32; https://link.springer.com/chapter/10.1007%2F174_2017_32
Springer Nature America, Inc
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know